Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Free Cash Flow (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Free Cash Flow for 4 consecutive years, with -$2.4 million as the latest value for Q4 2024.

  • Quarterly Free Cash Flow rose 25.84% to -$2.4 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$13.9 million through Dec 2024, down 8.37% year-over-year, with the annual reading at -$15.2 million for FY2025, 9.25% down from the prior year.
  • Free Cash Flow hit -$2.4 million in Q4 2024 for Pasithea Therapeutics, up from -$3.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$381845.0 in Q1 2021 to a low of -$4.6 million in Q3 2022.
  • Historically, Free Cash Flow has averaged -$2.6 million across 4 years, with a median of -$3.1 million in 2023.
  • Biggest five-year swings in Free Cash Flow: plummeted 743.68% in 2022 and later skyrocketed 30.51% in 2023.
  • Year by year, Free Cash Flow stood at -$1.8 million in 2021, then crashed by 86.55% to -$3.3 million in 2022, then decreased by 0.49% to -$3.3 million in 2023, then grew by 25.84% to -$2.4 million in 2024.
  • Business Quant data shows Free Cash Flow for KTTA at -$2.4 million in Q4 2024, -$3.1 million in Q3 2024, and -$4.0 million in Q2 2024.